Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Paula S. Norris is active.

Publication


Featured researches published by Paula S. Norris.


Nature Immunology | 2002

To kill or be killed: viral evasion of apoptosis

Chris A. Benedict; Paula S. Norris; Carl F. Ware

In the struggle between virus and host, control over the cells death machinery is crucial for survival. Viruses are obligatory intracellular parasites and, as such, must modulate apoptotic pathways to control the lifespan of their host in order to complete their replication cycle. Many of the counter-assaults mounted by the immune system incorporate activation of the apoptotic pathway—particularly by members of the tumor necrosis factor cytokine family—as a mechanism to restrict viral replication. Thus, apoptosis serves as a powerful selective pressure for the virus to evade. However, for the host, success is harsh and potentially costly, as apoptosis often contributes to pathogenesis. Here we examine some of the molecular mechanisms by which viruses manipulate the apoptotic machinery to their advantage and how we (as vertebrates) have evolved and learned to cope with viral evasion.


Nature Medicine | 2011

The tumor necrosis factor family member LIGHT is a target for asthmatic airway remodeling

Taylor A. Doherty; Pejman Soroosh; Naseem Khorram; Satoshi Fukuyama; Peter Rosenthal; Jae Youn Cho; Paula S. Norris; Heonsik Choi; Stefanie Scheu; Klaus Pfeffer; Bruce L. Zuraw; Carl F. Ware; David H. Broide; Michael Croft

Individuals with chronic asthma show a progressive decline in lung function that is thought to be due to structural remodeling of the airways characterized by subepithelial fibrosis and smooth muscle hyperplasia. Here we show that the tumor necrosis factor (TNF) family member LIGHT is expressed on lung inflammatory cells after allergen exposure. Pharmacological inhibition of LIGHT using a fusion protein between the IgG Fc domain and lymphotoxin β receptor (LTβR) reduces lung fibrosis, smooth muscle hyperplasia and airway hyperresponsiveness in mouse models of chronic asthma, despite having little effect on airway eosinophilia. LIGHT-deficient mice also show a similar impairment in fibrosis and smooth muscle accumulation. Blockade of LIGHT suppresses expression of lung transforming growth factor-β (TGF-β) and interleukin-13 (IL-13), cytokines implicated in remodeling in humans, whereas exogenous administration of LIGHT to the airways induces fibrosis and smooth muscle hyperplasia, Thus, LIGHT may be targeted to prevent asthma-related airway remodeling.


Proceedings of the National Academy of Sciences of the United States of America | 2009

Unconventional ligand activation of herpesvirus entry mediator signals cell survival

Timothy C. Cheung; Marcos W. Steinberg; Lisa M. Oborne; Matthew G. Macauley; Satoshi Fukuyama; Hideki Sanjo; Claire D'Souza; Paula S. Norris; Klaus Pfeffer; Kenneth M. Murphy; Mitchell Kronenberg; Patricia G. Spear; Carl F. Ware

The herpesvirus entry mediator (HVEM; TNFRSF14) activates NF-κB through the canonical TNF-related cytokine LIGHT, serving as a costimulatory pathway during activation of T cells. HVEM also functions as a ligand for the Ig superfamily members B and T lymphocyte attenuator (BTLA) and CD160, both of which limit inflammatory responses initiated by T cells. Emerging evidence indicates BTLA also promotes T cell survival, but its structural differences from LIGHT intimate BTLA is unlikely to function as an activator of HVEM. We demonstrate here that BTLA, CD160, and herpes simplex virus envelope glycoprotein D (gD) function as activating ligands for HVEM, promoting NF-κB activation and cell survival. Membrane-expressed BTLA and CD160, as well as soluble dimeric receptor surrogates BTLA-Fc and gD-Fc specifically activated HVEM-dependent NF-κB. BTLA and CD160 engagement induced recruitment of TNF receptor-associated factor 2 (TRAF2), but not TRAF3, to HVEM that specifically activated the RelA but not the RelB form of NF-κB in a mucosal epithelial tumor cell line. Moreover, Btla−/− T cells survived poorly following activation but were rescued with BTLA-Fc, indicating HVEM-BTLA bidirectional signaling may serve as a critical cell-survival system for lymphoid and epithelial cells.


Journal of Immunology | 2008

The Inhibitory HVEM-BTLA Pathway Counter Regulates Lymphotoxin β Receptor Signaling to Achieve Homeostasis of Dendritic Cells

Carl De Trez; Kirsten Schneider; Karen G. Potter; Nathalie M. Droin; James Fulton; Paula S. Norris; Sukwon Ha; Yang-Xin Fu; Theresa L. Murphy; Kenneth M. Murphy; Klaus Pfeffer; Chris A. Benedict; Carl F. Ware

Proliferation of dendritic cells (DC) in the spleen is regulated by positive growth signals through the lymphotoxin (LT)-β receptor; however, the countering inhibitory signals that achieve homeostatic control are unresolved. Mice deficient in LTα, LTβ, LTβR, and the NFκB inducing kinase show a specific loss of CD8− DC subsets. In contrast, the CD8α− DC subsets were overpopulated in mice deficient in the herpesvirus entry mediator (HVEM) or B and T lymphocyte attenuator (BTLA). HVEM- and BTLA-deficient DC subsets displayed a specific growth advantage in repopulating the spleen in competitive replacement bone marrow chimeric mice. Expression of HVEM and BTLA were required in DC and in the surrounding microenvironment, although DC expression of LTβR was necessary to maintain homeostasis. Moreover, enforced activation of the LTβR with an agonist Ab drove expansion of CD8α− DC subsets, overriding regulation by the HVEM-BTLA pathway. These results indicate the HVEM-BTLA pathway provides an inhibitory checkpoint for DC homeostasis in lymphoid tissue. Together, the LTβR and HVEM-BTLA pathways form an integrated signaling network regulating DC homeostasis.


Journal of Immunology | 2009

T Cell Intrinsic Heterodimeric Complexes between HVEM and BTLA Determine Receptivity to the Surrounding Microenvironment

Timothy C. Cheung; Lisa M. Oborne; Marcos W. Steinberg; Matthew G. Macauley; Satoshi Fukuyama; Hideki Sanjo; Claire D'Souza; Paula S. Norris; Klaus Pfeffer; Kenneth M. Murphy; Mitchell Kronenberg; Patricia G. Spear; Carl F. Ware

The inhibitory cosignaling pathway formed between the TNF receptor herpesvirus entry mediator (HVEM, TNFRSF14) and the Ig superfamily members, B and T lymphocyte attenuator (BTLA) and CD160, limits the activation of T cells. However, BTLA and CD160 can also serve as activating ligands for HVEM when presented in trans by adjacent cells, thus forming a bidirectional signaling pathway. BTLA and CD160 can directly activate the HVEM-dependent NF-κB RelA transcriptional complex raising the question of how NF-κB activation is repressed in naive T cells. In this study, we show BTLA interacts with HVEM in cis, forming a heterodimeric complex in naive T cells that inhibits HVEM-dependent NF-κB activation. The cis-interaction between HVEM and BTLA is the predominant form expressed on the surface of naive human and mouse T cells. The BTLA ectodomain acts as a competitive inhibitor blocking BTLA and CD160 from binding in trans to HVEM and initiating NF-κB activation. The TNF-related ligand, LIGHT (homologous to lymphotoxins, exhibits inducible expression, and competes with HSV glycoprotein D for HVEM, a receptor expressed by T lymphocytes, or TNFSF14) binds HVEM in the cis-complex, but NF-κB activation was attenuated, suggesting BTLA prevents oligomerization of HVEM in the cis-complex. Genetic deletion of BTLA or pharmacologic disruption of the HVEM-BTLA cis-complex in T cells promoted HVEM activation in trans. Interestingly, herpes simplex virus envelope glycoprotein D formed a cis-complex with HVEM, yet surprisingly, promoted the activation NF-κB RelA. We suggest that the HVEM-BTLA cis-complex competitively inhibits HVEM activation by ligands expressed in the surrounding microenvironment, thus helping maintain T cells in the naive state.


Cell Host & Microbe | 2013

Human Cytomegalovirus Glycoprotein UL141 Targets the TRAIL Death Receptors to Thwart Host Innate Antiviral Defenses

Wendell Smith; Peter Tomasec; Rebecca Aicheler; Andrea Loewendorf; Ivana Nemcovicova; Edward Chung Yern Wang; Richard James Stanton; Matt Macauley; Paula S. Norris; Laure Willen; Eva Ruckova; Akio Nomoto; Pascal Schneider; Gabriele Hahn; Dirk M. Zajonc; Carl F. Ware; Gavin William Grahame Wilkinson; Chris A. Benedict

Summary Death receptors (DRs) of the TNFR superfamily contribute to antiviral immunity by promoting apoptosis and regulating immune homeostasis during infection, and viral inhibition of DR signaling can alter immune defenses. Here we identify the human cytomegalovirus (HCMV) UL141 glycoprotein as necessary and sufficient to restrict TRAIL DR function. Despite showing no primary sequence homology to TNF family cytokines, UL141 binds the ectodomains of both human TRAIL DRs with affinities comparable to the natural ligand TRAIL. UL141 binding promotes intracellular retention of the DRs, thus protecting virus infected cells from TRAIL and TRAIL-dependent NK cell-mediated killing. The identification of UL141 as a herpesvirus modulator of the TRAIL DRs strongly implicates this pathway as a regulator of host defense to HCMV and highlights UL141 as a pleiotropic inhibitor of NK cell effector function.


Journal of Biological Chemistry | 2010

Allosteric Regulation of the Ubiquitin:NIK and Ubiquitin:TRAF3 E3 Ligases by the Lymphotoxin-β Receptor

Hideki Sanjo; Dirk M. Zajonc; Rebecca Braden; Paula S. Norris; Carl F. Ware

The lymphotoxin-β receptor (LTβR) activates the NF-κB2 transcription factors, p100 and RelB, by regulating the NF-κB-inducing kinase (NIK). Constitutive proteosomal degradation of NIK limits NF-κB activation in unstimulated cells by the ubiquitin:NIK E3 ligase comprised of subunits TNFR-associated factors (TRAF)3, TRAF2, and cellular inhibitor of apoptosis (cIAP). However, the mechanism releasing NIK from constitutive degradation remains unclear. We found that insertion of a charge-repulsion mutation in the receptor-binding crevice of TRAF3 ablated binding of both LTβR and NIK suggesting a common recognition site. A homologous mutation in TRAF2 inhibited cIAP interaction and blocked NIK degradation. Furthermore, the recruitment of TRAF3 and TRAF2 to the ligated LTβR competitively displaced NIK from TRAF3. Ligated LTβR complexed with TRAF3 and TRAF2 redirected the specificity of the ubiquitin ligase reaction to polyubiquitinate TRAF3 and TRAF2, leading to their proteosomal degradation. Stimulus-dependent degradation of TRAF3 required the RING domain of TRAF2, but not of TRAF3, implicating TRAF2 as a key E3 ligase in TRAF turnover. The combined action of competitive displacement of NIK and TRAF degradation halted NIK turnover, and promoted its association with IKKα and signal transmission. These results indicate the LTβR modifies the ubiquitin:NIK E3 ligase, and also acts as an allosteric regulator of the ubiquitin:TRAF E3 ligase.


Journal of Biological Chemistry | 2003

Structurally Distinct Recognition Motifs in Lymphotoxin-β Receptor and CD40 for Tumor Necrosis Factor Receptor-associated Factor (TRAF)-mediated Signaling

Chenglong Li; Paula S. Norris; Chao-Zhou Ni; Marnie L. Havert; Elizabeth M. Chiong; Bonnie R. Tran; Edelmira Cabezas; John C. Reed; Arnold C. Satterthwait; Carl F. Ware; Kathryn R. Ely

Lymphotoxin-β receptor (LTβR) and CD40 are members of the tumor necrosis factor family of signaling receptors that regulate cell survival or death through activation of NF-κB. These receptors transmit signals through downstream adaptor proteins called tumor necrosis factor receptor-associated factors (TRAFs). In this study, the crystal structure of a region of the cytoplasmic domain of LTβR bound to TRAF3 has revealed an unexpected new recognition motif, 388IPEEGD393, for TRAF3 binding. Although this motif is distinct in sequence and structure from the PVQET motif in CD40 and PIQCT in the regulator TRAF-associated NF-κB activator (TANK), recognition is mediated in the same binding crevice on the surface of TRAF3. The results reveal structurally adaptive “hot spots” in the TRAF3-binding crevice that promote molecular interactions driving specific signaling after contact with LTβR, CD40, or the downstream regulator TANK.


The EMBO Journal | 2015

Commensal microbiota influence systemic autoimmune responses

Jens Van Praet; Erin Donovan; Inge Vanassche; Michael Drennan; Fien Windels; Amélie Dendooven; Liesbeth Allais; Claude Cuvelier; Fons A. J. van de Loo; Paula S. Norris; Andrey A. Kruglov; Sergei A. Nedospasov; Raul Y. Tito; Jeroen Raes; Valérie Gaboriau-Routhiau; Nadine Cerf-Bensussan; Tom Van de Wiele; Gérard Eberl; Carl F. Ware; Dirk Elewaut

Antinuclear antibodies are a hallmark feature of generalized autoimmune diseases, including systemic lupus erythematosus and systemic sclerosis. However, the processes underlying the loss of tolerance against nuclear self‐constituents remain largely unresolved. Using mice deficient in lymphotoxin and Hox11, we report that approximately 25% of mice lacking secondary lymphoid organs spontaneously develop specific antinuclear antibodies. Interestingly, we find this phenotype is not caused by a defect in central tolerance. Rather, cell‐specific deletion and in vivo lymphotoxin blockade link these systemic autoimmune responses to the formation of gut‐associated lymphoid tissue in the neonatal period of life. We further demonstrate antinuclear antibody production is influenced by the presence of commensal gut flora, in particular increased colonization with segmented filamentous bacteria, and IL‐17 receptor signaling. Together, these data indicate that neonatal colonization of gut microbiota influences generalized autoimmunity in adult life.


Journal of Immunology | 2005

Human NK Cells Inhibit Cytomegalovirus Replication through a Noncytolytic Mechanism Involving Lymphotoxin-Dependent Induction of IFN-β

Ann-Charlotte Iversen; Paula S. Norris; Carl F. Ware; Chris A. Benedict

NK cells play a key role in host defense against the β-herpesvirus CMV through perforin-dependent cytolysis. In this study, we show that human NK cells can also control human CMV (HCMV) infection by a noncytolytic mechanism involving induction of IFN-β in the virus-infected cell. Both IL-2-activated primary NK cells and an IL-2-dependent NK cell line (NK-92) exhibited potent, noncytolytic anti-HCMV activity at very low E:T cell ratios (<0.1:1). Activated NK cells expressed lymphotoxin (LT)αβ on their cell surface, and secreted LTα and TNF, all of which contributed to the NF-κB-dependent release of IFN-β from infected fibroblasts. IFN-β produced by fibroblasts and NK cell-produced IFN-γ combined to inhibit HCMV replication after immediate early gene expression. These results highlight an efficient mechanism used by NK cells to activate IFN-β expression in the infected target cell that contributes to the arrest of virion production and virus spread without cellular elimination.

Collaboration


Dive into the Paula S. Norris's collaboration.

Top Co-Authors

Avatar

Chris A. Benedict

La Jolla Institute for Allergy and Immunology

View shared research outputs
Top Co-Authors

Avatar

Kenneth M. Murphy

Washington University in St. Louis

View shared research outputs
Top Co-Authors

Avatar

Timothy C. Cheung

La Jolla Institute for Allergy and Immunology

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Klaus Pfeffer

University of Düsseldorf

View shared research outputs
Top Co-Authors

Avatar

Lisa M. Oborne

La Jolla Institute for Allergy and Immunology

View shared research outputs
Top Co-Authors

Avatar

John R. Sedy

Washington University in St. Louis

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Christopher A. Nelson

Washington University in St. Louis

View shared research outputs
Researchain Logo
Decentralizing Knowledge